Abstract:Background and objectives: To develop and test the performance of the Positive Aβ Risk Score (PARS) for prediction of β-amyloid (Aβ) positivity in cognitively unimpaired individuals for use in clinical research. Detecting Aβ positivity is essential for identifying at-risk individuals who are candidates for early intervention with amyloid targeted treatments. Methods: We used data from 4,134 cognitively normal individuals from the Anti-Amyloid Treatment in Asymptomatic Alzheimer's (A4) Study. The sample was divided into training and test sets. A modified version of AutoScore, a machine learning-based software tool, was used to develop a scoring system using the training set. Three risk scores were developed using candidate predictors in various combinations from the following categories: demographics (age, sex, education, race, family history, body mass index, marital status, and ethnicity), subjective measures (Alzheimer's Disease Cooperative Study Activities of Daily Living-Prevention Instrument, Geriatric Depression Scale, and Memory Complaint Questionnaire), objective measures (free recall, Mini-Mental State Examination, immediate recall, digit symbol substitution, and delayed logical memory scores), and APOE4 status. Performance of the risk scores was evaluated in the independent test set. Results: PARS model 1 included age, body mass index (BMI), and family history and had an area under the curve (AUC) of 0.60 (95% CI 0.57-0.64). PARS model 2 included free recall in addition to the PARS model 1 variables and had an AUC of 0.61 (0.58-0.64). PARS model 3, which consisted of age, BMI, and APOE4 information, had an AUC of 0.73 (0.70-0.76). PARS model 3 showed the highest, but still moderate, performance metrics in comparison with other models with sensitivity of 72.0% (67.6%-76.4%), specificity of 62.1% (58.8%-65.4%), accuracy of 65.3% (62.7%-68.0%), and positive predictive value of 48.1% (44.1%-52.1%). Discussion: PARS models are a set of simple and practical risk scores that may improve our ability to identify individuals more likely to be amyloid positive. The models can potentially be used to enrich trials and serve as a screening step in research settings. This approach can be followed by the use of additional variables for the development of improved risk scores. Classification of evidence: This study provides Class II evidence that in cognitively unimpaired individuals PARS models predict Aβ positivity with moderate accuracy.

Machine learning prediction of future amyloid beta positivity in amyloid-negative individuals

Prediction of Amyloid β-Positivity with both MRI Parameters and Cognitive Function Using Machine Learning

Development and assessment of algorithms for predicting brain amyloid positivity in a population without dementia

Comparison of deep learning architectures for predicting amyloid positivity in Alzheimer's disease, mild cognitive impairment, and healthy aging, from T1-weighted brain structural MRI

A machine learning-based prediction of tau load and distribution in Alzheimer's disease using plasma, MRI and clinical variables

Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer’s disease

Precise Prediction of Cerebrospinal Fluid Amyloid Beta Protein for Early Alzheimer's Disease Detection Using Multimodal Data

Predicting Brain Amyloid Using Multivariate Morphometry Statistics, Sparse Coding, and Correntropy: Validation in 1,101 Individuals From the ADNI and OASIS Databases

Amyloid-β prediction machine learning model using source-based morphometry across neurocognitive disorders

Detecting Amyloid Positivity Using Morphometric Magnetic Resonance Imaging

Deep Learning-Based Prediction of PET Amyloid Status Using Multi-Contrast MRI

Predicting amyloid positivity from FDG-PET images using radiomics: A parsimonious model

Integrated Algorithm Combining Plasma Biomarkers and Cognitive Assessments Accurately Predicts Brain Β-Amyloid Pathology

Predicting Amyloid Positivity in Cognitively Unimpaired Older Adults: A Machine Learning Approach Using A4 Data

Network-based amyloid-beta pathology predicts subsequent cognitive decline in cognitively normal older adults

Comparative analysis of multimodal biomarkers for amyloid-beta positivity detection in Alzheimer's disease cohorts

Prediction of Amyloid Positivity in Patients with Subcortical Vascular Cognitive Impairment

Improved Prediction of Beta-Amyloid and Tau Burden Using Hippocampal Surface Multivariate Morphometry Statistics and Sparse Coding

PET-validated EEG-machine learning algorithm predicts brain amyloid pathology in pre-dementia Alzheimer's disease

Clinical Study of PET‐validated EEG‐machine learning algorithm predicting brain amyloid pathology in pre‐dementia Alzheimer’s disease